505074-55-5

Upstream product

• 6574-98-7 2,4-dichlorobenzylnitrile 
• 100-47-0 benzonitrile 
• 709036-64-6 1-(4-Chloro-phenyl)-2-(2,4-dichloro-phenyl)-4-hydroxy-4,5-dihydro-1H-imidazole-4-carboxylic Acid Ethyl Ester 
• 106-47-8 4-chloro-aniline 
• 505073-26-7 ethyl 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazole-4-carboxylate 
• 505073-24-5 2,4-dichloro-N-(4-chlorophenyl)benzenecarboximidamide 

Downstream Products

• 1055110-31-0 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazole-4-carbonyl chloride 
• 796875-39-3 5-chloro-1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazole-4-carboxylic acid 
• 505074-59-9 1-(4-chlorophenyl)-5-cyano-2-(2,4-dichlorophenyl)-1H-imidazole-4-carboxylic acid 
• 796875-38-2 tert-butyl 5-bromo-1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazole-4-carboxylate 
• 796875-37-1 tert-butyl 5-chloro-1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazole-4-carboxylate 
• 505074-57-7 tert-butyl 1-(4-chlorophenyl)-5-cyano-2-(2,4-dichlorophenyl)-1H-imidazole-4-carboxylate 
• 796875-40-6 5-bromo-1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazole-4-carboxylic acid 
• 709036-65-7 1-(4-Chloro-phenyl)-2-(2,4-dichloro-phenyl)-1H-imidazole-4-carboxylic Acid Methoxy-methyl-amide 
• 505074-56-6 tert-butyl 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazole-4-carboxylate 
• 527363-84-4 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-N-(4-morpholinyl)-1H-imidazole-4-carboxamide 
• 709036-68-0 1-[1-(4-Chloro-phenyl)-2-(2,4-dichloro-phenyl)-1H-imidazol-4-yl]-2-morpholin-4-yl-ethanone 
• 709036-66-8 1-[1-(4-Chloro-phenyl)-2-(2,4-dichloro-phenyl)-1H-imidazol-4-yl]-ethanone 
• 709036-67-9 2-Bromo-1-[1-(4-chloro-phenyl)-2-(2,4-dichloro-phenyl)-1H-imidazol-4-yl]-ethanone 
• 777054-28-1 C₂₂H₂₁Cl₃N₄O 

Relevant academic research and scientific papers

Optimization of imidazole amide derivatives as cannabinoid-1 receptor antagonists for the treatment of obesity

Several imidazole-based cyclohexyl amides were identified as potent CB-1 antagonists, but they exhibited poor oral exposure in rodents. Incorporation of a hydroxyl moiety on the cyclohexyl ring provided a dramatic improvement in oral exposure, together with a ca. 10-fold decrease in potency. Further optimization provided the imidazole 2-hydroxy-cyclohexyl amide 45, which exhibited hCB-1 Ki = 3.7 nM, and caused significant appetite suppression and robust, dose-dependent reduction of body weight gain in industry-standard rat models.

Bioisosteric replacements of the pyrazole moiety of rimonabant: Synthesis, biological properties, and molecular modeling investigations of thiazoles, triazoles, and imidazoles as potent and selective CB1 cannabinoid receptor antagonists

Series of thiazoles, triazoles, and imidazoles were designed as bioisosteres, based on the 1,5-diarylpyrazole motif that is present in the potent CB1 receptor antagonist rimonabant (SR141716A, 1). A number of target compounds was synthesized an

1 H-imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity

The present invention relates to a group of novel 1H-imidazole derivatives, to methods for the preparation of these compounds, and to pharmaceutical compositions containing one or more of these compounds as an active component. These 1H-imidazole derivati

PREPARATION OF IMIDAZOLE DERIVATIVES AND METHODS OF USE

This invention relates to imidazole compounds which are useful in promoting smoking cessation and maintaining abstinence.

Cannabinoid receptor ligands and uses thereof

Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment diseases, conditions and/or disorders modulated by cannabinoid receptor antagonists in animals are described herein.

Potent imidazole and triazole CB1 receptor antagonists related to SR141716

Diarylimidazolecarboxamides and diaryltriazolecarboxamides related to SR141716 were synthesized and tested for binding to the human CB1 receptor. Suitably substituted imidazoles are comparably potent to the clinical candidate, whereas the analo